Unknown

Dataset Information

0

Development of delivery methods for carbohydrate-based drugs: controlled release of biologically-active short chain fatty acid-hexosamine analogs.


ABSTRACT: Carbohydrates are attractive candidates for drug development because sugars are involved in many, if not most, complex human diseases including cancer, immune dysfunction, congenital disorders, and infectious diseases. Unfortunately, potential therapeutic benefits of sugar-based drugs are offset by poor pharmacologic properties that include rapid serum clearance, poor cellular uptake, and relatively high concentrations required for efficacy. To address these issues, pilot studies are reported here where 'Bu(4)ManNAc', a short chain fatty acid-monosaccharide hybrid molecule with anti-cancer activities, was encapsulated in polyethylene glycol-sebacic acid (PEG-SA) polymers. Sustained release of biologically active compound was achieved for over a week from drug-laden polymer formulated into microparticles thus offering a dramatic improvement over the twice daily administration currently used for in vivo studies. In a second strategy, a tributanoylated ManNAc analog (3,4,6-O-Bu(3)ManNAc) with anti-cancer activities was covalently linked to PEG-SA and formulated into nanoparticles suitable for drug delivery; once again release of biologically active compound was demonstrated.

SUBMITTER: Aich U 

PROVIDER: S-EPMC3038847 | biostudies-literature | 2010 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Development of delivery methods for carbohydrate-based drugs: controlled release of biologically-active short chain fatty acid-hexosamine analogs.

Aich Udayanath U   Meledeo M Adam MA   Sampathkumar Srinivasa-Gopalan SG   Fu Jie J   Jones Mark B MB   Weier Christopher A CA   Chung Sung Yun SY   Tang Benjamin C BC   Yang Ming M   Hanes Justin J   Yarema Kevin J KJ  

Glycoconjugate journal 20100511 4


Carbohydrates are attractive candidates for drug development because sugars are involved in many, if not most, complex human diseases including cancer, immune dysfunction, congenital disorders, and infectious diseases. Unfortunately, potential therapeutic benefits of sugar-based drugs are offset by poor pharmacologic properties that include rapid serum clearance, poor cellular uptake, and relatively high concentrations required for efficacy. To address these issues, pilot studies are reported he  ...[more]

Similar Datasets

| S-EPMC3725939 | biostudies-literature
| S-EPMC6292510 | biostudies-literature
| S-EPMC5026196 | biostudies-literature
| S-EPMC2657678 | biostudies-literature
2013-03-11 | GSE43065 | GEO
| S-EPMC3038843 | biostudies-literature
| S-EPMC6971417 | biostudies-literature
2018-06-13 | GSE31585 | GEO
| S-EPMC8234078 | biostudies-literature
| S-EPMC8585482 | biostudies-literature